Henry Schein, Inc. $HSIC Shares Sold by American Century Companies Inc.

American Century Companies Inc. reduced its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,512,290 shares of the company’s stock after selling 46,500 shares during the period. American Century Companies Inc. owned approximately 3.83% of Henry Schein worth $299,481,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its position in shares of Henry Schein by 47.3% in the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after buying an additional 9,756 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Henry Schein by 1.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after purchasing an additional 229 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Henry Schein in the 1st quarter valued at about $676,000. Asset Management One Co. Ltd. raised its holdings in shares of Henry Schein by 9.8% in the 2nd quarter. Asset Management One Co. Ltd. now owns 8,286 shares of the company’s stock valued at $605,000 after purchasing an additional 739 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Henry Schein by 24.8% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,272 shares of the company’s stock worth $458,000 after buying an additional 1,247 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Transactions at Henry Schein

In other Henry Schein news, CEO Stanley M. Bergman sold 38,346 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $81.01, for a total value of $3,106,409.46. Following the transaction, the chief executive officer owned 427,615 shares of the company’s stock, valued at approximately $34,641,091.15. This represents a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.08% of the company’s stock.

Analyst Ratings Changes

HSIC has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Mizuho upped their price target on shares of Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research report on Wednesday. Wall Street Zen raised shares of Henry Schein from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Evercore boosted their price target on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $85.58.

Henry Schein Price Performance

NASDAQ HSIC opened at $82.39 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.79 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The company has a 50-day moving average price of $77.85 and a two-hundred day moving average price of $72.15. The stock has a market cap of $9.45 billion, a price-to-earnings ratio of 25.20, a price-to-earnings-growth ratio of 2.41 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.04. The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Trending Headlines about Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.